CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.426
NA - Nord America 6.594
AS - Asia 5.625
SA - Sud America 857
AF - Africa 175
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 21.693
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.413
RU - Federazione Russa 4.141
SG - Singapore 2.385
CN - Cina 1.653
GB - Regno Unito 1.113
IT - Italia 697
BR - Brasile 684
HK - Hong Kong 574
DE - Germania 554
SE - Svezia 452
VN - Vietnam 424
FR - Francia 383
IE - Irlanda 370
FI - Finlandia 288
KR - Corea 160
NL - Olanda 118
CA - Canada 93
PL - Polonia 84
IN - India 70
JP - Giappone 68
ID - Indonesia 64
AR - Argentina 61
MX - Messico 52
UA - Ucraina 47
TG - Togo 42
ES - Italia 38
BJ - Benin 37
AT - Austria 35
BD - Bangladesh 32
ZA - Sudafrica 30
TR - Turchia 28
BE - Belgio 27
EC - Ecuador 24
VE - Venezuela 21
CO - Colombia 20
MA - Marocco 20
CZ - Repubblica Ceca 18
IQ - Iraq 16
PK - Pakistan 16
CL - Cile 15
IR - Iran 14
LT - Lituania 13
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
PH - Filippine 10
PY - Paraguay 10
KZ - Kazakistan 9
PE - Perù 9
AZ - Azerbaigian 8
KE - Kenya 8
NP - Nepal 8
SA - Arabia Saudita 8
TN - Tunisia 8
AU - Australia 7
CH - Svizzera 7
CR - Costa Rica 7
HN - Honduras 7
BO - Bolivia 6
EG - Egitto 6
JO - Giordania 6
KG - Kirghizistan 6
LV - Lettonia 6
UY - Uruguay 6
AM - Armenia 5
EU - Europa 5
IL - Israele 5
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
DK - Danimarca 4
DZ - Algeria 4
JM - Giamaica 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
NO - Norvegia 4
PA - Panama 4
SN - Senegal 4
TW - Taiwan 4
AO - Angola 3
DO - Repubblica Dominicana 3
GA - Gabon 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
BG - Bulgaria 2
BM - Bermuda 2
GR - Grecia 2
LU - Lussemburgo 2
LY - Libia 2
MY - Malesia 2
NI - Nicaragua 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
Totale 21.668
Salva come PNG Salva come JPEG
Città #
Moscow 1.402
Singapore 1.101
Dallas 991
Southend 901
Chandler 819
Ashburn 696
Hong Kong 566
Dublin 369
Beijing 350
Woodbridge 298
Munich 269
The Dalles 198
Jacksonville 195
New York 193
Los Angeles 187
Ann Arbor 181
Verona 166
Ho Chi Minh City 143
Lawrence 125
Princeton 125
Wilmington 114
Helsinki 108
Jinan 105
Houston 84
Hanoi 78
São Paulo 78
Redondo Beach 75
London 74
Turku 72
Tianjin 68
Buffalo 65
Sindelfingen 64
Tokyo 63
Santa Clara 62
Shenyang 60
Redmond 59
Milan 57
Meda 55
Nanjing 54
Seoul 53
Columbus 50
Hebei 50
Seattle 43
Warsaw 43
Lomé 42
Amsterdam 40
Cotonou 37
Jakarta 37
Guangzhou 36
Brooklyn 35
Washington 34
Montreal 33
Nanchang 33
Rome 32
Zhengzhou 32
Hangzhou 31
Kent 31
Denver 30
Frankfurt am Main 30
Nuremberg 30
San Francisco 30
Atlanta 29
Changsha 29
Chicago 29
Council Bluffs 29
Haikou 29
Stockholm 29
Brussels 27
Ningbo 27
Lappeenranta 26
Boardman 25
Chennai 24
Orem 24
Johannesburg 23
Phoenix 23
Dong Ket 22
Toronto 22
Rio de Janeiro 21
Belo Horizonte 20
Da Nang 20
Taiyuan 20
Taizhou 20
Vienna 20
Boston 19
Falls Church 18
Haiphong 18
Mexico City 18
Biên Hòa 17
Falkenstein 17
Jiaxing 17
Poplar 17
Fuzhou 16
Redwood City 16
Curitiba 14
Querétaro 14
Maceió 13
Norwalk 13
Porto Alegre 13
Augusta 12
Bologna 12
Totale 12.284
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 274
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 229
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 217
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 213
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 210
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 207
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 189
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 189
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 184
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 183
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 182
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 173
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 173
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 172
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 170
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 167
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 167
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 165
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 165
A multimodal approach to cancer-related cachexia: from theory to practice 164
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 162
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 160
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 158
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 156
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 155
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 153
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 152
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 151
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 151
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 149
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 148
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 148
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 147
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 146
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 145
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 143
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 143
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 143
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 142
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 141
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 141
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 141
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 139
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 139
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 139
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 139
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 139
Do immune checkpoint inhibitors need new studies methodology? 137
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 136
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 134
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 134
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 134
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 134
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 133
Exercise levels and preferences in cancer patients: a cross-sectional study 133
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 132
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 130
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 127
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 127
Exercise and anemia in cancer patients: could make the difference? 126
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 125
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 124
Muscle derangement and alteration of the nutritional machinery in NSCLC 123
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 122
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 122
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 121
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 120
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 119
Exercise oncology: It is time to make a change 119
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 118
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 117
A cross-sectional study exploring the perception of exercise oncology in the Italian population 117
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 117
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 117
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 117
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 116
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 116
Clinical meta-analyses of targeted therapies in adenocarcinoma. 115
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 115
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 115
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 114
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 114
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 114
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 112
Physical activity and exercise in lung cancer care: will promises be fulfilled? 112
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 112
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 112
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 111
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 111
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 111
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 110
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 110
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 108
Kinesiology students' perception regarding exercise oncology: a cross-sectional study 107
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 107
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 106
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 105
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 104
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 104
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 103
Totale 14.042
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.804
article - articoli 81.187
book - libri 0
conference - conferenze 991
curatela - curatele 0
other - altro 293
patent - brevetti 0
selected - selezionate 0
volume - volumi 333
Totale 165.608
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021350 0 0 0 0 0 88 29 16 24 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20254.541 230 184 209 791 148 200 201 192 708 351 435 892
2025/20269.532 848 732 1.103 2.374 3.708 767 0 0 0 0 0 0
Totale 22.014